The authorization for the Cuban-made injectable drug Heberprot-P to begin phase three of clinical trials in the United States is a new achievement by Cuban scientists and researchers from the biotechnological and pharmaceutical industry.»
The drug Heberprot-P continues is still the only one of its kind and very effective, 17 years after its registration in the Cuban health registry, on June 8, 2006.»
A unique investigation is underway in Sancti Spiritus, central Cuba, to provide new evidence on the efficacy of this drug»
The biopharmaceutical industry is one of the country's strategic economic sectors»
The registration of the pharmaceutical was announced in Havana in the first meeting of the Mexico-Cuba Health Cooperation Group»
According to BioCubaFarma enterprise, it is hoped that the Cuban developed medication will soon be available for patients in the United States»
Heberprot-p was created by a team of researchers from the Center for Genetic Engineering and Biotechnology (CIGB)»
The next meeting of the Russia-Cuba Health Working Group Intergovernmental Commission will be held in May»
Unique in the world to treat advanced foot ulcers in diabetic patients, the Cuban drug Heberprot-P has already been registered in 23 countries, it was informed today»
Specialists from at least 40 countries will assist to the International Congress “Controlling diabetes and its most severe complications”, to take place December 10th to 12th, in Varadero. »
Escambray ENGLISH EDITION